查詢結果分析
相關文獻
- Flutamide-Induced Liver Injury: A Case Report
- 攝護腺癌之化學藥物治療
- 攝護腺癌的放射線治療及其護理
- Free-to-total Serum Prostate Specific Antigen Ratio in Chinese Men
- 從末期攝護腺癌及乳癌來探討癌症病患荷爾蒙治療法之進展
- Detection of Prostatic Cancer Using Digital Rectal Examination, Prostate-Specific Antigen and Transrectal Ultrasonography
- Use of a Medical Decision Support System to Improve the Preoperative Diagnosis of Prostate Cancer with Pelvic Lymph Node Metastases
- Prostatic Carcinoma Presenting as Rectal Stenosis--A Case Report
- 攝護腺肥大患者之潛伏攝護腺癌
- 攝護腺癌的放射線治療
頁籤選單縮合
題 名 | Flutamide-Induced Liver Injury: A Case Report=Flutamide引起肝臟傷害:一病例報告 |
---|---|
作 者 | 朱正偉; 黃信彰; 羅景全; 蔡世豪; 李重賓; 黃以信; 張扶陽; 李壽東; | 書刊名 | 中華醫學雜誌 |
卷 期 | 61:11 1998.11[民87.11] |
頁 次 | 頁678-682 |
分類號 | 415.53 |
關鍵詞 | 藥物引起肝臟傷害; 攝護腺癌; Roussel uclaf因果關係法; Drug-induced liver injury; Flutamide; Prostate cancer; Roussel uclaf causality assessment method; |
語 文 | 英文(English) |
中文摘要 | Flutamide為一非類固醇之抗雄性激素製劑,自美國1989年2月核准上市以來,已 被用於治療攝護腺癌。它對肝藏的潛在毒性在西方國家曾報告過,但其實際機轉並不清楚, 可能是籍由細胞色素P-450系統產生的活性代謝物引起的特異性免疫肝臟反應。 在此我們報告一位72歲病人,有經過6個月的flutamide治療攝護腺癌後,發生全身疲 倦、食慾不振、噁心和黃疸之症狀。他過去並有肝臟疾病史及服用其它藥物史。肝臟生化檢 查顯示alanine aminotransferase及aspartate aminotransferase分別上升至1,035 U/I和745 U/I; 總膽紅素則高至7.0 mg/dl;血清急性病毒性肝炎指標均是陰性反應;血清抗核抗體、抗粒 腺體抗體及抗平滑肌抗體亦呈陰性反應。經皮穿肝切片顯示:肝臟中央靜脈周圍區域壞死及 急性橋狀壞死。病人在停用flutamide後即有臨床改善,肝臟功能並在flutamide停用後3個 月完全恢復。以Roussel Uclaf因果關係法算出分數達到8分,而確定診斷為藥物性肝炎。 這個病例提醒我們,病人在接受flutamide治療中,需規則的追蹤並監測其肝臟生化功能。 |
英文摘要 | Flutamide is a nonsteroidal antiandrogen agent. Since it was marketed in February of 1989 in the USA for treatment of prostate cancer, its potential for hepatotoxicity has been reported in Western countries. Here we report the case of a 72-year-old patient who suffered from general malaise, poor appetite, nausea and jaundice after six months of flutamide therapy for the treatment of prostate cancer. He had no past history of liver disease and was not receiving other medications. Liver biochemistries revealed elevated serum alanine aminotransferase and aspartate aminotransferase concentrations of up to 1,035 U/I and 745 U/I, respectively. Serum total bilirubin concentration was elevated to 7.0 mg/dl. Serologic markers for acute viral hepatitis were all negative. Serum antinuclear antibody, antimitochondrial antibody and antismooth-muscle antibody were also negative. Percutaneous liver biopsy revealed pericentral zonal necrosis with bridging hepatic necrosis. The patient's clinical symptoms and signs began to improve after discontinuation of flutamide, and his liver function had returned to normal there months later. Roussel Uclaf causality assessment for adverse drug reaction confirmed the diagnosis of drug-induced liver injury. This case reminds us that patients who are receiving flutamide should be regularly monitored for liver function. If drug-induced liver injury is suspected, flutamide must be discontinued promptly to avoid progression of liver injury. |
本系統中英文摘要資訊取自各篇刊載內容。